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A B S T R A C T
Aim was to investigate expression of Ki-67, P53 and progesterone receptors (PR) in leiomyomas (LM), smooth muscle
tumors of uncertain malignant potential (STUMP) and leiomyosarcomas (LMS) and to establish possible usefulness of
these three parameters in distinguishing between LM and STUMP, and STUMP and LMS. Retrospective study of 51
uterine smooth muscle neoplasm (16 LM, 18 STUMP, 17 LMS) technically acceptable for analyses from years 2002–2007
from Department of Gynecological and Prenatal Pathology, University Hospital Center Zagreb, Croatia. Immunohisto-
chemical analysis of Ki-67, P53 and PR expression was performed. Every nuclei stained brown, regardless of shade
intensivity, was considered positive. The interpretation of immunohistochemical staining was expressed as number of
positive cells in 100 cell count in most active area of the slide. Non-parametric analysis of variance Kruskal-Walis test
was performed. Ki-67 expression was negative in all LM and higher than 5% in 12/18 STUMP and 10/17 LMS. Signifi-
cant differences were observed between LM and STUMP expression for Ki-67 (p=0.000), and LM and LMS expression
for Ki-67 (p=0.000).There was no expression of P53 in LM, expression of P53 was found in 7/17 LMS and 5/18 STUMP.
Expression of P53 was significant between LM and LMS (p=0.002), and between LM and STUMP (p=0.006). Expres-
sion of PR was found in 16/16 LM and 18/18 STUMP, 10/17 LMS did not show PR expression. Expression of PR was sig-
nificant between LM and LMS (p=0.018) and STUMP and LMS (p=0.004). The findings of our study in concordance
with other study results are helpful information establishing more diagnostic criteria and parameters for diagnosis in
doubtful cases between three entities. Immunoassaying for Ki-67, P53 and PR are such parameters. The panel of their ex-
pression in specific case eases diagnosis.
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Introduction
Smooth muscle uterine neoplasms are most common
female genital tract neoplasms. Usually they are classi-
fied as: leiomyomas (LM), smooth muscle tumors of un-
certain malignant potential (STUMP) and leimyosar-
comas (LMS)1–4. Principal consideration factors for this
classification are: mitotic index, nuclear atypia, presence
and extent of coagulation necrosis and other morphologi-
cal features such as age and tumor size1–6. LM of the
uterus is the most frequent smooth muscle neoplasms oc-
curring in almost 40% of women over 35 years of age4.
Their clinical outcome is excellent. STUMP are charac-
terized by lower mitotic index and/or less nuclear atypia
and/or absent or minimal presence of coagulative necro-
sis and more favorable clinical outcome than LMS1,7–8.
Incidence of STUMP in literature available to authors is
usually described as rare without exact figures1–4. LMS
are rare, making about 1.3% of all uterine malignant
neoplasms and 16% of malignant mesenchymal neopla-
sms are LMS. Approximately 1 out of 800 smooth muscle
tumors is LMS1. Clinical course and outcome are usually
rapid and unfavorable. Local recurrence and metastasis
risk is high, with overall 5-year survival from 12 to 25%1.
Varieties of prognostic factors were studied in LMS with
unanimous agreement on clinical significance only for
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extent of tumor at the moment of diagnosis1,9–14. Antigen
Ki-67 is a nuclear protein expressed in all active phases
of the cell cycle except G015. It is regarded as an indicator
of cell proliferative activity and biological agressivity16.
High expression of Ki-67 was found in LMS versus
LM7,17–19, but studies comparing LM, STUMP and LMS
are rare7,18,20–21. Nuclear protein P53 is present in many
normal human cells in non-detectable amounts22. P53
gene mutations are frequent in human neoplasm devel-
opment and mutant P53 is accumulated in high quan-
tities19,22. LMS show higher P53 expression than other
smooth muscle uterine neoplasms7,20–21,23. Monoclonal
mouse anti-human progesterone receptor is intended for
use in semi-quantitative detection of progesterone recep-
tor (PR) by light microscope. Reactivity of normal myo-
metrium is characterized with high staining intensity4.
Expression of PR is higher in LM and STUMP than in
LMS7,20–21,24–25. In the available literature, uniform mor-
phological features such as mitotic count, type of mi-
toses, presence and extension of coagulation necrosis, tu-
mor size, tumor border, tumor growth pattern are all
relevant for establishing diagnoses of various smooth
muscle uterine neoplasms1–6. Still, variations in interpre-
tation and subjective identifications of some of these fea-
tures (mitotic figures, type of necrosis) have resulted in
introduction of new diagnostic methods and criteria in
diagnostics of these neoplasms. Immunohistochemical
methods for expression analysis of various factors have
been Investigated1–28. Discrepancies between approaches
to evaluation of results of the particular method continu-
ally gives rise to new researches and consensus reaching.
Different methods and procedures26 were applied and
used in effort to solve the mentioned dilemma. We were
focused on diagnostic methods, adequate for use in rou-
tine practice, results of which would provide additional
information to facilitate correct diagnosis achievement
process. The aim of the present study was to investigate
expression of Ki-67, P53 and progesterone receptor (PR)
in LM, STUMP and LMS and to establish possible use-
fulness of these three parameters combined with other
morphological features in distinguishing between LM
and STUMP, and STUMP and LMS. We used method of
exact and easily applicable morphometric analysis (pre-
cise number of positive cells in the total number of cells,
presented as a percentage of positive cells).
Materials and Methods
At the Department of Gynecological and Prenatal Pa-
thology of the University Hospital Center Zagreb, 3661
cases of smooth muscle neoplasms were diagnosed dur-
ing the 2002–2007 period: 25(0.68%) STUMP, 43 (1.17%)
LMS, and 3593 (98.15%) LM. For the purposes of this
retrospective study we used neoplasms that met all the
criteria (neoplasms were surgically removed in their en-
tirety by hysterectomy, the amount of tissue embedded in
paraffin blocks was satisfactory, materials from patients
who underwent surgery in other hospitals were exclu-
ded); there were 18/25 STUMP, 17/43 LMS. The equal
number of LM was chosen by random sampling. This ret-
rospective study includes 16 cases of LM, 18 cases of
STUMP and 17 cases of LMS. All technically acceptable
cases are from 2002 to 2007 from Department of Gyne-
cological and Prenatal Pathology, University Hospital
Center Zagreb, Croatia. Diagnosis of LM, STUMP and
LMS was based on previously published criteria1–4. All
tissue specimens were obtained from surgically removed
tumors. Tissue was fixed in formalin and cut to thickness
of 5 mm from paraffin-embedded blocks. All haematoxy-
lin eosin slides and all imunohistochemical slides for each
case were reviewed by three experienced pathologist.
Immunohistochemistry
Paraffin-embedded tumor sections were deparaffini-
zed and stained in automated platform DakoCytomation
using monoclonal mouse anti-human Ki-67 antigen (Da-
ko, Glostrup, Denmark), monoclonal mouse anti-human
P53 protein (Dako, Glostrup, Denmark), and monoclonal
mouse anti-human progesterone receptor (PR) clone:
PgR 636 (Dako, Glostrup, Denmark). Criteria for positiv-
ism and negativism of cell nuclei were based on data, sug-
gestions and photographs published in recent notebook
of immunohistochemistry29. Every nucleus stained brown,
regardless of shade intensivity, was considered positive.
The interpretation of immunohistochemical staining was
expressed as number of positive cells in 100 cell count in
most active area of the slide. PC Image analysis software
ISSA 3.1 VAMS Zagreb, Croatia was used. Results were
divided in three categories: negative, 1–10% positive cells
and more than 11% positive cells.
Statistical analysis
The SPSS 11.5 for Windows (SPSS inc., Chicago IL,
USA) was used. Analyses of frequencies and non-para-
metric analysis of variance Kruskal-Wallis test were
performed. (p<0.05 was considered statistically signifi-
cant).
Results
Ki-67 expression
Expression of Ki-67 was negative in 16/16 LM, 4/18
STUMP and 4/17 LMS. 1–5% of cells were positive in
8/18 STUMP and 3/17 LMS. Expression was positive in
more than 15% of cells of 9/17 LMS. Mean expression of
Ki-67 in LM is 0, 9.3% in STUMP and 14.4% in LMS.
Statistically significant differences in Ki-67 expression
was found between LM and STUMP (p=0.000, Tables 1
and 2) and between LM and LMS (p=0.000, Tables 1
and 2, Figure 1).
P53 expression
Expression of P53 was negative in 16/16 LM, 11/18
STUMP and 9/17 LMS. Expression of P53 in 1–10% of
cells showed 5/17 STUMP and 2/17 LMS. Expression in
>20% of cells showed 5/17 LMS. Median expression of
P53 in LM is 0, 4.1% in STUMP and 17.5% in LMS. A sig-
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nificant difference in expression of P53 was seen between
LM and LMS (p=0.002, Table 1 and 2), as well as between
LM and STUMP (p=0.006, Table 1 and 2, Figure 1).
PR expression
Expression of PR11% was positive in 16/16 LM,
18/18 STUMP, and 7/17 LMS. 10/17 LMS showed no PR
expression, while 16/18 STUMP showed expression in
51% cells. Median expression of PR in LM was 68.3%, in
STUMP 72.2% and in LMS 28.6%. A significant difference
in expression of PR was seen between LM and LMS
(p=0.018, Table 1 and 2), and STUMP and LMS (p=0.004,
Tables 1 and 2, Figure 1)
Discussion and Conclusion
The results in our study showed significant difference
in Ki-67 expression between LM and STUMP as well as
between LM and LMS. Expression of P53 was differed
significantly between LM and LMS, and between STUMP
and LM. There was a significant difference in PR expres-
sion between LM and LMS, as well as between STUMP
and LMS. In spite of relatively clearly defined criteria1–5,
differential pathological diagnosis between LM, especia-
lly atypical LM with bizarre looking nuclei, and STUMP.
And STUMP versus LMS can be difficult, particularly as-
sessment of malignant potential and clinical outcome.
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TABLE 2
EXPRESSION OF KI-67, P53 AND PR IN LM, STUMP AND LMS
Tumor Ki-67 p53 PR
LM 0† 0† 64.1±14.9
(27–90)†
STUMP 9.3±13.5
(0–40)†
4.1±8.3
(0–30)†
72.2±20.1
(11–98)†
LMS 14.4±13.3
(0–42)†
17.5±26.9
(0–80)†
28.6±40
(0–100)†
*Abbreviations: LM – leiomyoma, STUMP – smooth muscle tu-
mor of uncertain malignant potential, LMS – leiomyosarcoma
†means±SE (range)
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Fig. 1. Expression of Ki-67, p53 and PR in LM, STUMP and LMS; PR – progesterone receptors LM – leiomyoma, STUMP – smooth
muscle tumor of uncertain malignant potential, LMS – leiomyosarcoma.
TABLE 1
NUMBER OF LM, STUMP AND LMS POSITIVE FOR KI-67 AND P53 CONSIDERING POSITIVE CELLS COUNT
% Expression
Ki-67 p 53 PR
LM
N
STUMP
N
LMS
N
LM
N
STUMP
N
LMS
N
LM
N
STUMP
N
LMS
N
0 16 4 4 16 11 9 0 0 10
1–10 0 8 4 0 5 2 0 0 0
11 0 6 9 0 2 6 16 18 7
Total 16 18 17 16 18 17 16 18 17
*Abbreviations: LM – leiomyoma, STUMP – smooth muscle tumor of uncertain malignant potential, LMS – leiomyosarcoma
† N – number of cases
The criteria for establishing diagnosis of LM, STUMP
and LMS has been constantly changing over the years
from the initial and essential significance of the number
of mitoses, nuclear atypia to the current significance of
the presence of coagulation necrosis. Notorious problem
of mitotic figure recognition in neoplasms full of clumped
and degenerately changed nuclei and cells7 is recognized.
No convention of the applied criteria proved to be com-
pletely safe and clear in establishing diagnosis. The pub-
lished literature investigated presence and expression of
the proliferative factors and hormone receptors in the
cells of the smooth muscle neoplasms. Those papers
stated the results for restricted number of cases, which
motivated us to contribute to the research of the expres-
sion of the proliferative factors P53, Ki-67, and PR by in-
vestigating our own material. Additional factors and
their parameters are needed and welcomed in effort to
distinguish these two entities. We are aware that the re-
stricted number of cases and relative difficulties in com-
paring the obtained results to the existing findings, due
to the different evaluation criteria for the expression of
the P53, Ki-67 and PR, may result in defective interpre-
tation. We have chosen to measure expression of Ki-67,
P53 and PR as a number of positive cells/100 cells count
because it is acceptable and affordable in every day’s
practice. Achieved number is an absolute number but
can also represent a percentage of positive cells. Unified
measure of expression represents a path toward the most
representative result of immunohistochemistry analysis
with a potential of facilitating the process of diagnosing
various types of smooth muscle neoplasms. Every nuclei
stained brown, regardless of shade intensivity, was con-
sidered positive. The interpretation of immunohistoche-
mical staining was expressed as number of positive cells
in 100 cells count in most active area of the slide. We
compared our data with previously presented studies.
None of them investigate immunoreactivity for P53,
Ki-67 and PR in all three groups of uterine smooth mus-
cle neoplasms, which make comparison of results some-
what difficult. Zhai et collaborates18 found less than 5%
reactivity for P53 in all LM and O’Neill et al.23 found re-
activity for P53 in 1/10 LM. In our study all LM did not
show reactivity for P53. There are no results of P53 reac-
tivity, to the best of author’s knowledge, in STUMP so we
could no compare our results. Zhai et collaborates18 found
reactivity for P53 in half of their LMS (7/14), we found
P53 reactivity in third (6/17) of our LMS. Zhai et colla-
borates18 based their results of Ki-67 reactivity on the
number of positive cells per 10 high power fields (HPF)
of microscope and their results can not be compared with
others. Amada et al.19 didn’t found reactivity of Ki-67 in
LM, Mayerhofer et al.27 found reactivity of Ki-67 in one
tenth (2/25) of LM and O’Neil et al.23 found Ki-67 reac-
tivity in two fifths (4/10) of LM. We didn’t found Ki-67 re-
activity in our LM. Mayerhofer et al.27 didn’t found Ki-67
reactivity (0/22) in STUMP and O’Neill et al.23 found Re-
activity for Ki-67 in half (2/4) of STUMP. We found reac-
tivity for Ki-67 in three fifths (14/18) of STUMP. Amada
et al.19 found 3.6% reactivity for Ki-67 in nine tenths
(21/24) of LMS and 15% reactivity for Ki-67 in three
fifths (14/24) of LMS, Mayerhofer et al.27 found reactivity
for Ki-67 in half (10/20) of LMS and O’Neil et al.23 found
reactivity for Ki-67 in four fifths (20/22) of LMS. Three
fourths (13/17) of our LMS show reactivity for Ki-67.
Bodner et al.28 found reactivity for PR in two fifths (9/21)
of LMS and Leitao et al.24 found reactivity of PR in one
third (9/25) of LMS. In our study two fifths (7/11) of LMS
show PR reactivity. Akhan et al.21 found in their study of
24 LMS that PR expression over 10% has positive effects
on patient’s survival. The findings of our study are in
concordance with other studies results and are helpful
information establishing more diagnostic criteria for di-
agnosis in doubtful cases between three entities. Major
diagnostic features, as number of mitoses per 10 HPF,
nuclear atypia, presence and extent of coagulation necro-
sis, tumor borders, tumor size, clinical stage1–5, could be
insufficient for accurate diagnosis because of tissue con-
dition (clumped or degenerate nuclei) or amount of tu-
mor tissue and relation to surrounding myometrium
(laparoscopic methods used) so additional relevant pa-
rameters are needed. Immunostaining for Ki-67, P53
and PR are such parameters. The panel of their expres-
sion in specific case eases diagnosis.
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EKSPRESIJA KI-67, P53 I PROGESTERONSKIH RECEPTORA U GLATKOMO[I]NIM TUMORIMA
MATERNICE. DIJAGNOSTI^KA VRIJEDNOST
S A @ E T A K
Cilj rad je istra`iti ekspresiju Ki-67, p53 i progesteronskih receptora (PR) u leiomiomima (LM), glatkomi{i}nim
tumorima nepoznata zlo}udnog potencijala (STUMP) i leiomiosarkomima (LMS), te utvrditi mogu}u korisnost ta tri
promatrana parametra u olak{avanju razlikovanja LM, STUMP i LMS. U~injena je retrospektivna studija 51 glatko-
mi{i}nog tumora (16 LM, 18 STUMP, 17 LMS), tehni~ki pogodnih za analizu, dijagnosticiranih u Zavodu za ginekolo{ku
i perinatalnu patologiju Klini~kog bolni~kog centra Zagreb u razdoblju 2002.–2007. godine. Izvr{ena je imunohisto-
kemijska analiza ekspresije Ki-67, p53 i PR. Statisti~ka analiza u~injena je primjenom ne-parametrijskih metoda ana-
lize varijance Kruskal-Walis-ovim testom. U svim LM nije na|ena ekspresija Ki-67, ekspresija Ki-67 vi{a od 5% na|ena
je u 12/18 STUMP i 10/17 LMS. Zna~ajna je razlika u ekspresiji Ki-67 izme|u LM i STUMP (p=0,000) te izme|u LM i
LMS (p=0,000). Nije na|ena ekspresija p53 u LM. Ekspresija p53 na|ena je u 7/17 LMS i 5/18 STUMP. Zna~ajna je
razlika u ekspresiji p53 izme|u LM i LMS (p=0,002) te izme|u LM i STUMP (p=0,006). Ekspresija PR na|ena je u
16/16 LM i 18/18 STUMP, dok 10/17 LMS nije pokazalo nikakvu ekspresiju PR. Zna~ajna je razlika u ekspresiji PR
izme|u LM i LMS (p=0,018) te izme|u STUMP i LMS (p=0,004). Nalazi na{e studije u suglasju s rezultatima drugih
studija su korisna novost u utvr|ivanju novih dijagnosti~kih kriterija i parametara za olak{avanje postavljanja dijag-
noze u nejasnim slu~ajevima ova tri entiteta. Imunohistokemijsko utvr|ivanje ekspresije Ki-67, p53 i PR, te panel
rezultata njihove ekspresije olak{ava dijagnozu u pojedinim nejasnim slu~ajevima.
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